Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

导出原文传递

翻译打印收藏纠错

作者： Ignace,Vergote ^[1] ; Jose Alejandro,Pérez-Fidalgo ^[2] ; Erika Paige,Hamilton ^[3] ; Giorgio,Valabrega ^[4] ; Toon,Van Gorp ^[1] ; Jalid,Sehouli ^[5] ; David,Cibula ^[6] ; Tally,Levy ^[7] ; Stephen,Welch ^[8] ; Debra L,Richardson ^[9] ; Eva M,Guerra ^[10] ; Giovanni,Scambia ^[11] ; Stéphanie,Henry ^[12] ; Pauline,Wimberger ^[13] ; David S,Miller ^[14] ; Jaroslav,Klat ^[15] ; Jerónimo,Martínez-Garcia ^[16] ; Francesco,Raspagliesi ^[17] ; Bhavana,Pothuri ^[18] ; Ignacio,Romero ^[19] ; Alice,Bergamini ^[20] ; Brian,Slomovitz ^[21] ; Fabienne,Schochter ^[22] ; Estrid,Høgdall ^[23] ; Lorena,Fariñas-Madrid ^[24] ; Bradley J,Monk ^[25] ; Dayana,Michel ^[26] ; Michael G,Kauffman ^[26] ; Sharon,Shacham ^[26] ; Mansoor Raza,Mirza ^[27] ; Vicky,Makker ^[28] ; ENGOT-EN5/GOG-3055/SIENDO Investigators

作者单位： BGOG, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. ^[1] INCLIVA, CIBERONC, GEICO, Hospital Clinico Universitario de Valencia, Spain. ^[2] Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN. ^[3] MITO and Department of Oncology, University of Torino, Mauriziano Hospital, Turin, Italy. ^[4] Department of Gynecology, NOGGO, European Competence Center for Ovarian Cancer, Charité Comprehensive Cancer Center, Charité-Berlin University of Medicine, Berlin, Germany. ^[5] CEEGOG, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ^[6] Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, ISGO, Wolfson Medical Center, Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel. ^[7] London Health Sciences Centre, London, ON, Canada. ^[8] Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK. ^[9] GEICO, Hospital Universitario Ramon y Cajal, Madrid, Spain. ^[10] MITO, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. ^[11] CHU UCL Namur Site Ste Elisabeth, Service d'onco-hématologie (SORMN), BGOG and Université Catholique de Louvain, Namur, Belgium. ^[12] Department of Obstetrics and Gynecology, University Hospital Carl Gustav Carus, NOGGO and Technische Universitat Dresden, Dresden, Germany. ^[13] Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. ^[14] University Hospital Ostrava and University of Ostrava, Ostrava-Poruba, Czech Republic. ^[15] Department of Oncology, GEICO, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. ^[16] Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy. ^[17] NYU Langone Health, Perlmutter Cancer Center, New York University School of Medicine, New York, NY. ^[18] Medical Oncology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. ^[19] Department of Obstetrics and Gynecology, San Raffaele Milano, Milano, Italy.;Università Vita-Salute San Raffaele, Milano, Italy. ^[20] Mount Sinai Medical Center, Florida International University, Miami, FL. ^[21] Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany. ^[22] Department of Pathology, Herlev Hospital Copenhagen University Hospital, Copenhagen, Denmark. ^[23] Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain. ^[24] GOG, HonorHealth, University of Arizona, Creighton University, Phoenix, AZ. ^[25] Karyopharm Therapeutics, Newton, MA. ^[26] Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark. ^[27] Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY. ^[28]